APEIRON Biologics AG
42 articles about APEIRON Biologics AG
APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
APEIRON Respiratory Therapies GmbH announces positive final results from a Phase I clinical trial of inhaled APN01, a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2.
APEIRON shareholders approve new group structure geared towards enabling innovation and growth
APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group through the demerger of its preclinical and clinical development activities and the creation of a new fully separate holding company, invIOs Holding AG.
Clinical Catch-Up: October 11-15
10/18/2021It was yet another busy week for clinical trial announcements. Take a look.
APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01
APEIRON Biologics AG, a privately held biotechnology company developing novel immunotherapies for cancer and respiratory diseases, today announced the start of a company sponsored Phase 1 trial for inhalation of APN01.
APEIRON Biologics' APN01 Selected for Large-Scale US Trial in COVID-19
APEIRON Biologics AG announced the next development steps for APN01 for the treatment of COVID-19.
BioSpace Global Roundup, Nov. 12
11/12/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials
At least three different biotech companies are working on two ACE2-related drugs to find a solution to the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19
Regulatory approvals obtained for the treatment of 200 COVID-19 patients in Austria, Germany and Denmark; Austrian government to provide significant financial support
APEIRON to present preclinical data at the 2019 AACR-NCI-EORTC Conference
APEIRON Biologics AG announced that it will present preclinical data for its clinical stage project APN401 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 26-30 October 2019 in Boston, MA, USA.
APEIRON to present preclinical APN401 data at the 2019 ESMO Congress
APEIRON Biologics AG announced that it will present its development program and data from ongoing preclinical studies of APN401.
APEIRON Announces Collaboration with Lead Discovery Center GmbH
Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach
APEIRON EXPANDS EXECUTIVE BOARD AND APPOINTS DR. ANDERSON GAWECO AS CHIEF MEDICAL AND SCIENTIFIC OFFICER (CMSO)
APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).
APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer
The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor
Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi
Evotec and Apeiron announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015.
APEIRON and Evotec Achieve First Milestone in Immuno-Oncology Alliance With Sanofi
The milestone payment of € 3 million will be split equally between the two biotech companies.
APEIRON to Present at the Biotech Showcase Annual Conference on January 9, 2018
APEIRON today announced that it will present at Biotech Showcase 2018, to be held January 8-10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing.